Research programme: cell movement inhibitors - Pharmaxon
Alternative Names: PR-22GLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator CNRS; Schafer-N; Universite de la Mediterranee; University Medical Center Hamburg-Eppendorf
- Developer Pharmaxon
- Class
- Mechanism of Action Cell movement inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in France (Parenteral)
- 19 Jul 2007 Preclinical trials in Glioblastoma in France (Parenteral)